Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Divarasib (GDC-6036) is an investigational, oral, high-potency and selective KRAS G12C inhibitor with an IC50 of < 0.01 μM. Divarasib irreversibly locks KRAS G12C oncoprotein in an inactive state and inhibits tumor cell growth. It is being investigated for use in solid tumors, including non-small cell lung and colorectal cancers and other types of cancer.
Description | Divarasib (GDC-6036) is an investigational, oral, high-potency and selective KRAS G12C inhibitor with an IC50 of < 0.01 μM. Divarasib irreversibly locks KRAS G12C oncoprotein in an inactive state and inhibits tumor cell growth. It is being investigated for use in solid tumors, including non-small cell lung and colorectal cancers and other types of cancer. |
Targets&IC50 | KRAS G12C:<0.01 μM |
In vitro | Divarasib exhibits a potency with an EC50 value of 2 nM in K-Ras G12C-alkylation HCC1171 cells.[2] |
In vivo | Administration of Divarasib (10-100 mg/kg/day; PO for 7 days) results in a reduction in the ratio of free KRAS G12C.[1] |
Synonyms | GDC-6036 |
Molecular Weight | 622.06 |
Formula | C29H32ClF4N7O2 |
CAS No. | 2417987-45-0 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
DMSO: 90.0 mg/mL (144.7 mM), Need ultrasonic
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Divarasib 2417987-45-0 GPCR/G Protein MAPK Ras GDC-6036 Inhibitor inhibitor inhibit